Kobayashi Pharmaceutical Co (KBYPF) Stock Forecast & Price Target

Compare

6 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KBYPF Analyst Ratings

Hold

0 Buy

1 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Kobayashi

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KBYPF Stock 12 Month Forecast

Average Price Target

$35.26

▼(-6.67%Downside)

Based on 1 Wall Street analysts offering 12 month price targets for Kobayashi Pharmaceutical Co in the last 3 months. The average price target is $35.26 with a high forecast of $35.26 and a low forecast of $35.26. The average price target represents a -6.67% change from the last price of $37.78.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"$31","35":"$35","39":"$39","43":"$43","47":"$47"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.2563,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.2563,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,35,39,43,47],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Jul<br/>2024","9":"Sep<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.9,36.773561538461536,36.64712307692307,36.52068461538462,36.394246153846154,36.26780769230769,36.14136923076923,36.01493076923077,35.88849230769231,35.76205384615385,35.635615384615384,35.50917692307693,35.382738461538466,{"y":35.2563,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.9,36.77384615384615,36.6476923076923,36.52153846153846,36.395384615384614,36.26923076923077,36.14307692307692,36.01692307692308,35.89076923076923,35.76461538461538,35.638461538461534,35.512307692307694,35.386153846153846,{"y":35.26,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.9,36.773561538461536,36.64712307692307,36.52068461538462,36.394246153846154,36.26780769230769,36.14136923076923,36.01493076923077,35.88849230769231,35.76205384615385,35.635615384615384,35.50917692307693,35.382738461538466,{"y":35.2563,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.2,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":45.08,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":39.1,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.2,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.8,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":33.91,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":32.5,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":38.18,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.83,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":37.83,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.36,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.36,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.26

Average Price Target$35.26

Lowest Price Target$35.26

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yuji OhanaNomura

Nomura

$38.01→$35.24

Hold

-6.72%

Downside

Reiterated

06/04/25

Nomura Remains a Hold on Kobayashi Pharmaceutical Co (KBYPF)

Hisae KawamotoJefferies

Jefferies

$35.93

Hold

-4.89%

Downside

Reiterated

03/21/25

Jefferies Reaffirms Their Hold Rating on Kobayashi Pharmaceutical Co (KBYPF)

Wakako SatoMorgan Stanley

Morgan Stanley

$40.08→$41.46

Hold

9.74%

Upside

Reiterated

09/25/24

Kobayashi Pharma Co Ltd. (4967:JP) PT Raised to JPY6,000 at Morgan StanleyMorgan Stanley analyst Wakako Sato raised the price target on Kobayashi Pharma Co Ltd. (4967:JP) to JPY6,000.00 (from JPY5,800.00) while maintaining a Equalweight rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yuji OhanaNomura

Nomura

$38.01→$35.24

Hold

-6.72%

Downside

Reiterated

06/04/25

Nomura Remains a Hold on Kobayashi Pharmaceutical Co (KBYPF)

Hisae KawamotoJefferies

Jefferies

$35.93

Hold

-4.89%

Downside

Reiterated

03/21/25

Jefferies Reaffirms Their Hold Rating on Kobayashi Pharmaceutical Co (KBYPF)

Wakako SatoMorgan Stanley

Morgan Stanley

$40.08→$41.46

Hold

9.74%

Upside

Reiterated

09/25/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

KBYPF Analyst Recommendation Trends

Rating

Sep 24

Nov 24

Mar 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KBYPF has received 0 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. KBYPF average Analyst price target in the past 3 months is 35.26.

Each month's total comprises the sum of three months' worth of ratings.

KBYPF Financial Forecast

KBYPF Earnings Forecast

Next quarter’s earnings estimate for KBYPF is $0.17 with a range of $0.17 to $0.17. The previous quarter’s EPS was $0.15. KBYPF beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year KBYPF has Preformed in-line its overall industry.

KBYPF Sales Forecast

Next quarter’s sales forecast for KBYPF is $265.45M with a range of $258.25M to $273.13M. The previous quarter’s sales results were $225.31M. KBYPF beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year KBYPF has Preformed in-line its overall industry.

KBYPF Stock Forecast FAQ

What is KBYPF’s average 12-month price target, according to analysts?

Based on analyst ratings, Kobayashi Pharmaceutical Co Ltd’s 12-month average price target is 35.26.

What is KBYPF’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for KBYPF, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KBYPF a Buy, Sell or Hold?

Kobayashi Pharmaceutical Co Ltd has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.

What is Kobayashi Pharmaceutical Co Ltd’s price target?

The average price target for Kobayashi Pharmaceutical Co Ltd is 35.26. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.26 ,the lowest forecast is $35.26. The average price target represents -6.67% Decrease from the current price of $37.78.

What do analysts say about Kobayashi Pharmaceutical Co Ltd?

Kobayashi Pharmaceutical Co Ltd’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of KBYPF?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Kobayashi Pharmaceutical Co (KBYPF) Stock Forecast & Price Target

KBYPF Analyst Ratings

KBYPF Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

KBYPF Analyst Recommendation Trends

KBYPF Financial Forecast

KBYPF Earnings Forecast

KBYPF Sales Forecast

KBYPF Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts